logo

Last Update

This profile was last updated on 8/14/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Gary Frashier?

Gary E. Frashier

Chairman and Chief Executive Officer

OSI Pharmaceuticals , Inc.

HQ Phone:  (631) 962-2000

Direct Phone: (516) ***-****direct phone

Email: g***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

OSI Pharmaceuticals , Inc.

41 Pinelawn Road

Melville, New York,11747

United States

Company Description

OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality and novel pharmaceutical products designed to extend life and/or improve the quality of life for patients with cancer and diab...more

Find other employees at this company (12)

Background Information

Employment History

Executive Vice President

Millipore Corporation


Managing Partner

Targeted Technology


President and Chief Executive Officer of Waters Chromatography Subsidiary

Waters Corporation


Strategic Partner

SV Life Sciences


President and Chief Executive Officer

OSIP


Affiliations

BioMed SA

Board Member


Achillion Pharmaceuticals Inc

Board Member


MERRIMACK PHARMACEUTICALS INC

Founder


Apex Bioventures Acquisition Corp

Director


Metric Medical Devices Inc

Board Member


ViroXis Corporation

Board Member


Santalis Corporation

Advisor


StemBioSys Inc.

Board Member


America Stem Cell , Inc.

Business Advisory Board Member


Management Associates

President and Principal


Boston Life Sciences , Inc.

Board Member


MIT Sloan

Fellow


Inex Pharmaceuticals Corporation

Board Member


MDS Capital Corp.

Board Member


Xeris Pharmaceuticals , Inc.

Board Member


Eutropics Pharmaceuticals Inc

Founder


Massachusetts Institute of Technology

Member, Advisory Boards


Young Presidents' Organization Inc

Member


Education

B.S

Chemical Engineering

Texas Tech


M.B.A.

Massachusetts Institute


M.S.

Management

M.I.T


Web References(111 Total References)


Targeted Technology | Gary Frashier

www.rt-designs.com [cached]

Gary Frashier, MBA, PE
Gary Frashier Managing Partner Gary Frashier brings extensive experience to the Fund, having served as a Chief Executive Officer for over 24 years in life science and specialty chemicals, and has over 17 years of experience in international operations. Gary served as the CEO and Chairman of OSI Pharmaceuticals, Inc, and it was during his nine year tenure at OSI that the leading genetic-based cancer drug, "Tarceva", was discovered and developed through proof-of-concept human clinical trials. Tarceva is now sold globally by Roche, Genentech and Astellas for the treatment of many solid tumors with sales of over $1.9 Billion per year. OSI was acquired by Astellas in 2010 for a price of $4 Billion. Prior to OSI, Gary served as Executive Vice President of Millipore Corporation and as President of their International Operations. When Millipore acquired Waters Corporation, he served as President and CEO of their Waters Chromatography subsidiary. Prior to this, he joined Genex Corporation, which discovered, developed and patented the first single-chain antibodies. Gary financed over $250 Million in capital for his companies from a combination of equity fundings and other sources, and is a Strategic Partner in SV Life Sciences, a major Boston venture capital company. Gary has served as a founder of several life sciences companies, including Merrimack Pharmaceuticals, Eutropics, America Stem Cell, and Apex BioVentures Acquisition Corporation. He has also served on the Board of Directors of Maxim Pharma, Merrimack Pharma, Tekmira, Exegenics, Aderis Pharma, and Alseres Pharma, and is currently on the Boards of Achillion Pharmaceuticals, (NASDAQ:ACHN), ViroXis Corporation, StemBioSys and Metric Medical. Gary has a BS in Chemical Engineering from Texas Tech University and an MS from the Massachusetts Institute of Technology in Management (Alfred P. Sloan Fellow).


Targeted Technology | Press Releases 2013

rt-designs.com [cached]

Santalis is advised by a renowned group of industry and clinical experts, including Dr. Ronald L. Moy (past President of the American Academy of Dermatology; www.aad.org), Catherine Burzik (former CEO of KCI) and Gary Frashier (former CEO of OSI Pharmaceuticals).


Targeted Technology | Gary Frashier

www.rt-designs.com [cached]

Gary Frashier, MBA, PE
Targeted Technology | Gary Frashier Targeted Technology Gary Frashier, MBA, PE Gary Frashier Managing Partner Gary Frashier brings extensive experience to the Fund, having served as a Chief Executive Officer for over 24 years in life science and specialty chemicals, and has over 17 years of experience in international operations. Gary served as the CEO and Chairman of OSI Pharmaceuticals, Inc, and it was during his nine year tenure at OSI that the leading genetic-based cancer drug, "Tarceva", was discovered and developed through proof-of-concept human clinical trials. Tarceva is now sold globally by Roche, Genentech and Astellas for the treatment of many solid tumors with sales of over $1.9 Billion per year. OSI was acquired by Astellas in 2010 for a price of $4 Billion. Prior to OSI, Gary served as Executive Vice President of Millipore Corporation and as President of their International Operations. When Millipore acquired Waters Corporation, he served as President and CEO of their Waters Chromatography subsidiary. Prior to this, he joined Genex Corporation, which discovered, developed and patented the first single-chain antibodies. Gary financed over $250 Million in capital for his companies from a combination of equity fundings and other sources, and is a Strategic Partner in SV Life Sciences, a major Boston venture capital company. Gary has served as a founder of several life sciences companies, including Merrimack Pharmaceuticals, Eutropics, America Stem Cell, and Apex BioVentures Acquisition Corporation. He has also served on the Board of Directors of Maxim Pharma, Merrimack Pharma, Tekmira, Exegenics, Aderis Pharma, and Alseres Pharma, and is currently on the Boards of Achillion Pharmaceuticals, (NASDAQ:ACHN), ViroXis Corporation, StemBioSys and Metric Medical. Gary has a BS in Chemical Engineering from Texas Tech University and an MS from the Massachusetts Institute of Technology in Management (Alfred P. Sloan Fellow).


Board of Directors | Metric

metricmd.com [cached]

Gary E. Frashier
Board of Directors Mr. Frashier is President and Principal of Management Associates, and he brings extensive experience in life science management, operations and transactions, having served as a CEO for twenty-four years in life sciences and specialty chemicals. Prior to the founding of Management Associates, Mr. Frashier served as Chief Executive Officer and Chairman of OSI Pharmaceuticals, and it was during his tenure at OSI that the leading genetic-based cancer drug, "Tarceva" was discovered and developed thru initial human Proof of Concept clinical trials. Mr. Frashier has raised over $250 million from a combination of equity financings and other sources, has organized many collaborations and joint programs with major pharmaceutical companies, and has served as a founder of several life science companies. Prior to OSI, Mr. Frashier served as President, International, and Executive Vice President of Millipore Corporation; President and CEO of Waters Corporation, the leader in liquid chromatography; and CEO of Genex Corporation, a protein engineering company. He has participated as a founder in organizing several biotechnology companies, including Merrimack Pharmaceuticals, Inc.; Eutropics, Inc.; America Stem Cell, Inc.; and Apex BioVentures Acquisition Corporation. He currently serves on the Board of Directors of Achillion Pharmaceuticals, Inc. (NASDAQ), ViroXis Corporation, Inc., and Metric Medical Devices, Inc., and he is an Advisor to Santalis Corporation and StemBioSys. He is a Strategic Partner in SV Life Sciences LP, a major venture capital company. He has served on numerous other private and public life science company Boards, including Maxim Pharmaceuticals, Tekmira Pharmaceuticals (Canada), Apex BioVentures Acquisition Corporation, Tanox, Inc., Cytoclonal Pharmaceuticals, Exegenics Pharmaceuticals, Aderis Pharmaceuticals, and Alseres Pharmaceuticals. Mr. Frashier has a B.S. in Chemical Engineering from Texas Tech University, which has designated him a "Distinguished Engineer Graduate," and an M.B.A. from the Massachusetts Institute of Technology, where he was selected as an "Alfred P. Sloan Fellow.


stembiosys.com

Gary E. Frashier
"StemBioSys has done an excellent job developing its unique stem cell technology. The company is ready to move to the next level." - Gary E. Frashier Gary Frashier's skill in the development and commercialization of life sciences technologies and companies is evident in his long list of highly productive investment rounds and profitable exits. As CEO of OSI Pharmaceuticals he oversaw the development of Tarceva, a cancer drug eventually marketed by Roche and Genentech and currently generating $1.7 billion in annual sales. OSI was acquired for $4 billion in 2010 and in addition Mr. Frashier has raised more than $250 million in equity and other sources for a wide variety of life science companies. His executive leadership experience includes CEO and president positions with Millipore Corp., Waters Corp. and Genex Corp. Mr. Frashier has founded or co-founded several biotechnology companies including Merrimack Pharmaceuticals, Eutropics and Apex BioVentures Acquisition Corp. He serves as a director or advisor with of many of these and other life science companies. Mr. Frashier is a strategic partner with SV Life Sciences, a major venture capital company. He also serves as president and principal of Management Associates. Mr. Frashier holds a B.S. in chemical engineering from Texas Tech University and an M.B.A. from the Massachusetts Institute of Technology.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory